Loading patent…
AssigneeAdvanced Accelerator Applications SA
InventorsDonato Barbato, Clementina Brambati, Stefano Buono, Daniela Chicco, Francesco de Palo, Lorenza Fugazza, Maribel Lopera-Sierra, Maurizio Mariani, Giovanni Tesoriere
Estimating the term…
The present invention relates to methods of treating cancers that overexpress somatostatin receptors, e.g. neuroendocrine tumors (NET). In particular, the invention provides novel therapies based on the combination of a peptide receptor radionuclide therapeutic (PRRT) agent and immuno-oncology (I-O) therapeutic agents, wherein said I-O therapeutic agents are selected from the group consisting of LAG-3 inhibitors, TIM-3 inhibitors, GITR angonists, TGF-β inhibitors, IL15/IL-15RA complex, and selected PD-1 inhibitors.
(canceled)
A method of treating a somatostatin receptor over-expressing cancer in a subject, comprising administering to the subject a combination of a peptide receptor radionuclide therapeutic (PRRT) agent and one or two immuno-oncology (I-O) therapeutic agent(s), wherein said I-O therapeutic agent(s) is(are) selected from the group consisting of an LAG-3 inhibitor, a TIM-3 inhibitor, a GITR angonists, a TGF-β inhibitor, an IL15/IL-15RA complex, and a PD-1 inhibitor, wherein said PD-1 inhibitor is selected from the group consisting of Spartalizumab, Pembrolizumab, Pidilizumab, Durvalomab, Atezolizumab, Avelumab, MED10680, REGN2810, TSR-042, PF-06801591, BGB-A317, BGB-108, INCSHR1210, and AMP-224.
A formulation comprising a peptide receptor radionuclide therapeutic (PRRT) agent, and one or two immuno-oncology (I-O) therapeutic agent(s), wherein said I-O therapeutic agent(s) is(are) selected from the group consisting of an LAG-3 inhibitor, a TIM-3 inhibitor, a GITR angonists, a TGF-β inhibitor, an IL15/IL-15RA complex, and a PD-1 inhibitor, wherein said PD-1 inhibitor is selected from the group consisting of Spartalizumab, Pembrolizumab, Pidilizumab, Durvalomab, Atezolizumab.
Dependencies are inferred from the claim text.